DE-LYCRA
26.7.2022 14:02:28 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, today announced a partnership with Browzwear that will provide designers using VStitcher and Lotta, the pioneering platforms for 3D fashion design, the ability to quickly and easily develop products incorporating fabrics containing LYCRA®, LYCRA® T400®, and COOLMAX® fibers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005001/en/
The partnership with Browzwear is the latest element of a multifaceted digital transformation that The LYCRA Company began last year with the launch of the LYCRA ONE™ customer portal, an online marketplace connecting brands, retailers, and garment makers to a global network of partner mills in a virtual capacity. The expansion of The LYCRA Company’s digital infrastructure is enabling new forms of engagement with its global customer base, and online platforms, like Browzwear, demonstrate the differentiation and sources of innovation that The LYCRA Company is helping bring to its customers across the apparel value chain.
With the true-to-life visualizations made possible with Browzwear's innovative software, the industry's leading 3D software for apparel design and development, designers can digitally create activewear, denim, swimwear, ready-to-wear, and intimate apparel fashions using fabrics showcased in the LYCRA® Brand Materials Library. The Browzwear platform enables designers to visualize how garments made with LYCRA® fiber offer a comfortable, lasting fit that will move with the wearer.
All the materials with digital versions in the LYCRA® Brand Materials Library can be sourced directly from one of 15 global mills initially featured on Browzwear. These materials have been tested and certified by The LYCRA Company, ensuring they contain the company’s authentic fibers that are designed to meet consumer needs for comfort, fit and ease of movement. In addition, The LYCRA Company will continue to work with Browzwear to add new resources to the materials library as they become available, further enhancing the digital design capabilities.
This partnership also advances The LYCRA Company’s sustainability commitment to offering a variety of fiber and fabric solutions that reduce or divert waste and keep materials in use longer. Creating digital garments via Browzwear streamlines the production process and reduces the need to manufacture samples, saving time and reducing waste for more efficient and sustainable operations.
“At The LYCRA Company, innovation is in our DNA, and we constantly look at new ways to create value for our mill customers, brands, and retail partners," said Julien Born, CEO of The LYCRA Company. "Digital transformation and sustainability offer opportunities, but also stretch our approach to innovation as fast and meaningful advances in those areas cannot be achieved alone. By teaming up with Browzwear, we are taking an important step in that direction, with the goal of ultimately changing the way the apparel industry will engage and interact digitally to optimize the sourcing of high-quality fabrics that extend garment wear life and reduce the need for samples.”
" We are thrilled to collaborate with The LYCRA Company and enable our users to leverage its well-known performance fibers to better incorporate them into designs, faster, easier, and more sustainably. Our Fabric Analyzer ensures the 3D versions of fabrics made with fibers from the LYCRA® Brand Materials Library result in true-to-life simulations of the garments, with physics and movement that reflect the durability and unique functionality of these fibers,” said Avihay Feld, Browzwear co-founder and CEO. “We believe this partnership will drive positive impact throughout the industry by helping brands and retailers to operate a more sustainable, efficient development process."
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® and COOLMAX® are trademarks of The LYCRA Company.
About Browzwear
Founded in 1999, Browzwear is a pioneer of 3D digital solutions for the fashion industry, driving seamless processes from concept to commerce. For designers, Browzwear accelerates collection development, opening limitless opportunities to create iterations of styles. For technical designers and pattern makers, Browzwear rapidly fits graded garments with accurate, true-motion material replication. For manufacturers, Browzwear’s Tech Pack delivers everything needed to produce physical garments perfectly the first time, and at every step from design to production. Worldwide, more than 650 organizations such as Columbia Sportswear, PVH Group and VF Corporation leverage Browzwear’s open platform to streamline processes, collaborate and pursue data-driven production strategies so they can sell more while manufacturing less, which increases both ecologic and economic sustainability. For more information, visit www.browzwear.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom